$0.34
−19.84%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.37
From 52W high−88.70%
Volume1.64M
Market cap$14.99M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.37
From 52W high
−88.70%
Volume
1.64M
Market cap
$14.99M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
36.6
MomentumView details →
1D Return
−19.84%
YTD Return
−79.89%
SummaryUpdated Jun 1, 2026
Estrella Immunopharma, Inc. (NASDAQ:ESLA) is a preclinical-stage biopharmaceutical company founded to develop innovative T-cell therapies for treating blood cancers and solid tumors. Based in Emeryville, California, the company went public in September 2021 and focuses on developing engineered T-cell immunotherapies designed to harness the body's immune system to fight cancer. As a preclinical company, Estrella has not yet generated revenue and remains in the research and development phase of bringing its therapeutic candidates through clinical trials toward potential commercialization.
Similar companies
Latest newsMore news →
Estrella Immunopharma, Inc. announced that the first patient in the STARLIGHT-1 dose-expansion phase tolerated two EB103 infusions of 5 × 10⁶ T cells/kg, given three weeks apart, well during the first month, with no treatment-related serious adverse events reported.4d agoEstrella Immunopharma, Inc. announced that Intermountain Health Platte Valley Hospital LDS Hospital has been activated as the fifth clinical site for its ongoing STARLIGHT-1 Phase I/II trial of EB103 in patients with relapsed B-cell non-Hodgkin's lymphoma.6d agoEstrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.70d ago